Cushing Syndrome Market Size, Share and Growth Outlook, 2026

Cushing Syndrome Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Cushing Syndrome Market size is forecast to increase from $446.47 Billion in 2026 to $802.21 Billion in 2034 at a CAGR of 7.6% between 2026 and 2034.

The Cushing Syndrome market report provides detailed analysis and outlook of Cushing Syndrome segments including By Treatment Type (Medical Therapy, Surgical Treatment, Radiation Therapy, Combination Therapy), By Diagnosis Method (Biochemical Tests, Imaging Techniques, Petrosal Sinus Sampling), By End-User (Hospitals & Clinics, Specialty Endocrinology Centers, Diagnostic Laboratories) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Cushing Syndrome Industry Overview

Regulatory Progress Accelerating New Treatment Opportunities

The Cushing syndrome industry is witnessing significant momentum as pharmaceutical developers advance novel therapies aimed at addressing the complex metabolic and endocrine complications associated with excess cortisol production. A major focus of the industry is the continued development of relacorilant by Corcept Therapeutics Incorporated. Following constructive discussions with the U.S. Food and Drug Administration regarding a previous Complete Response Letter, the company announced plans to resubmit its New Drug Application after completing targeted secondary analyses requested by regulators. The regulatory pathway highlights the importance of robust efficacy evaluation in therapies targeting endogenous Cushing syndrome. The anticipated review process has attracted considerable attention from clinicians, researchers, and investors due to the potential introduction of an additional treatment option for patients suffering from chronic hypercortisolism and its associated complications.

Pivotal Clinical Data Strengthening Evidence-Based Treatment Development

Clinical research remains a major driver of innovation within the Cushing syndrome industry. The publication of data from Corcept Therapeutics’ Phase 3 GRACE trial in The Lancet Diabetes & Endocrinology has provided important insights into the efficacy and safety profile of relacorilant. The multicenter study followed 152 patients diagnosed with endogenous Cushing syndrome and generated detailed clinical evidence supporting the therapeutic potential of cortisol receptor modulation. These published findings serve as a key scientific foundation for ongoing regulatory submissions and future treatment adoption. As healthcare providers seek therapies capable of addressing both the hormonal and metabolic consequences of excessive cortisol exposure, high-quality clinical evidence is becoming increasingly important in shaping treatment guidelines and supporting informed clinical decision-making across endocrinology practices.

Pipeline Expansion Targeting Metabolic Complications of Hypercortisolism

The Cushing syndrome industry is also benefiting from the advancement of new investigational therapies focused on managing the metabolic consequences of chronic cortisol excess. Sparrow Pharmaceuticals, Inc. has initiated targeted clinical studies evaluating clofutriben (SPI-62), an investigational therapy designed to assess the relationship between dosage levels and improvements in glycemic control. The research specifically focuses on individuals experiencing type 2 diabetes associated with hypercortisolism, a common and clinically significant complication of Cushing syndrome. By exploring therapies that address both cortisol dysregulation and related metabolic disorders, pharmaceutical developers are expanding the scope of treatment strategies available for this complex endocrine condition. The growing emphasis on precision dosing, metabolic outcomes, and patient-specific therapeutic approaches reflects the broader movement toward more comprehensive management of Cushing syndrome and its systemic health impacts.

Cushing Syndrome Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Cushing Syndrome market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Corcept Therapeutics, Inc., Novartis AG, Recordati Rare Diseases (Recordati S.p.A.), Xeris Biopharma Holdings, Inc., Ipsen Biopharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc., Pfizer Inc., Sparrow Pharmaceuticals, HRA Pharma (Perrigo Company plc), SteroTherapeutics. The Cushing Syndrome market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Cushing Syndrome industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Cushing Syndrome Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Cushing Syndrome companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Cushing Syndrome markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Cushing Syndrome Market Competitive Benchmarking and Company Analysis

Leading companies in Cushing Syndrome industry include- Corcept Therapeutics, Inc., Novartis AG, Recordati Rare Diseases (Recordati S.p.A.), Xeris Biopharma Holdings, Inc., Ipsen Biopharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc., Pfizer Inc., Sparrow Pharmaceuticals, HRA Pharma (Perrigo Company plc), SteroTherapeutics. The Cushing Syndrome market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Cushing Syndrome Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Cushing Syndrome market remains one of the strongest-performing segments in the country.
The US Cushing Syndrome Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Cushing Syndrome market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Cushing Syndrome industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Cushing Syndrome markets

Canada's strong Cushing Syndrome sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Cushing Syndrome market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Cushing Syndrome Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Cushing Syndrome market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Cushing Syndrome population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Cushing Syndrome industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Cushing Syndrome market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Cushing Syndrome sales through 2034

France Cushing Syndrome companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Cushing Syndrome Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Cushing Syndrome distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Cushing Syndrome Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Cushing Syndrome market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Cushing Syndrome industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Cushing Syndrome industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Cushing Syndrome Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Cushing Syndrome market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Cushing Syndrome market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Cushing Syndrome Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Cushing Syndrome Market Segmentation

By Treatment Type
Medical Therapy
Surgical Treatment
Radiation Therapy
Combination Therapy
By Diagnosis Method
Biochemical Tests
Imaging Techniques
Petrosal Sinus Sampling
By End-User
Hospitals & Clinics
Specialty Endocrinology Centers
Diagnostic Laboratories

Top Companies in Cushing Syndrome Industry

Corcept Therapeutics, Inc.
Novartis AG
Recordati Rare Diseases (Recordati S.p.A.)
Xeris Biopharma Holdings, Inc.
Ipsen Biopharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc.
Pfizer Inc.
Sparrow Pharmaceuticals
HRA Pharma (Perrigo Company plc)
SteroTherapeutics

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025